thalidomide has been researched along with Acne Inversa in 12 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with apremilast has recently demonstrated clinically meaningful improvement in moderate hidradenitis suppurativa (HS)." | 9.30 | Apremilast for moderate hidradenitis suppurativa: no significant change in lesional skin inflammatory biomarkers. ( Davelaar, N; Mus, AMC; Prens, EP; van der Zee, HH; van Doorn, MBA; Vossen, ARJV, 2019) |
| "We report the "real-life" use of apremilast in the treatment of multimorbid patients with hidradenitis suppurativa and review its potential role in the management of this severe condition." | 9.05 | Apremilast for the treatment of hidradenitis suppurativa associated with psoriatic arthritis in multimorbid patients: Case report and review of literature. ( De Simone, C; Garcovich, S; Giovanardi, G; Malvaso, D; Peris, K, 2020) |
| "Effective anti-inflammatory treatments for hidradenitis suppurativa (HS) are limited." | 6.90 | Apremilast for moderate hidradenitis suppurativa: Results of a randomized controlled trial. ( Prens, EP; van der Zee, HH; van Doorn, MBA; Vossen, ARJV, 2019) |
| "Treatment with apremilast has recently demonstrated clinically meaningful improvement in moderate hidradenitis suppurativa (HS)." | 5.30 | Apremilast for moderate hidradenitis suppurativa: no significant change in lesional skin inflammatory biomarkers. ( Davelaar, N; Mus, AMC; Prens, EP; van der Zee, HH; van Doorn, MBA; Vossen, ARJV, 2019) |
| "We report the "real-life" use of apremilast in the treatment of multimorbid patients with hidradenitis suppurativa and review its potential role in the management of this severe condition." | 5.05 | Apremilast for the treatment of hidradenitis suppurativa associated with psoriatic arthritis in multimorbid patients: Case report and review of literature. ( De Simone, C; Garcovich, S; Giovanardi, G; Malvaso, D; Peris, K, 2020) |
| "Effective anti-inflammatory treatments for hidradenitis suppurativa (HS) are limited." | 2.90 | Apremilast for moderate hidradenitis suppurativa: Results of a randomized controlled trial. ( Prens, EP; van der Zee, HH; van Doorn, MBA; Vossen, ARJV, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (58.33) | 24.3611 |
| 2020's | 5 (41.67) | 2.80 |
| Authors | Studies |
|---|---|
| Agud-Dios, M | 1 |
| Arroyo-Andrés, J | 1 |
| Rubio-Muñiz, C | 1 |
| Postigo-Lorente, C | 1 |
| Lanna, C | 1 |
| Mazzilli, S | 1 |
| Zangrilli, A | 1 |
| Bianchi, L | 1 |
| Campione, E | 1 |
| Garcovich, S | 1 |
| Giovanardi, G | 1 |
| Malvaso, D | 1 |
| De Simone, C | 1 |
| Peris, K | 1 |
| Proietti, I | 1 |
| Michelini, S | 1 |
| Mambrin, A | 1 |
| Di Fraia, M | 1 |
| Tolino, E | 1 |
| Balduzzi, V | 1 |
| Bernardini, N | 1 |
| Marchesiello, A | 1 |
| Porta, N | 1 |
| Skroza, N | 1 |
| Romeo, G | 1 |
| Di Cristofano, C | 1 |
| Petrozza, V | 1 |
| Potenza, C | 1 |
| Aarts, P | 2 |
| Vossen, ARJV | 4 |
| van der Zee, HH | 4 |
| Prens, EP | 4 |
| van Straalen, KR | 2 |
| Dudink, K | 1 |
| Ardon, CB | 1 |
| Weber, P | 1 |
| Seyed Jafari, SM | 1 |
| Yawalkar, N | 1 |
| Hunger, RE | 1 |
| Davelaar, N | 1 |
| Mus, AMC | 1 |
| van Doorn, MBA | 2 |
| Kerdel, FR | 1 |
| Azevedo, FA | 1 |
| Kerdel Don, C | 1 |
| Don, FA | 1 |
| Fabbrocini, G | 1 |
| Kerdel, FA | 1 |
| Hotz, C | 1 |
| Sbidian, E | 1 |
| Ingen-Housz-Oro, S | 1 |
| Chosidow, O | 1 |
| Wolkenstein, P | 1 |
| Reddick, CL | 1 |
| Singh, MN | 1 |
| Chalmers, RJ | 1 |
2 reviews available for thalidomide and Acne Inversa
| Article | Year |
|---|---|
Apremilast for the treatment of hidradenitis suppurativa associated with psoriatic arthritis in multimorbid patients: Case report and review of literature.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Psoriatic; Hidradenitis Suppurativa; Human | 2020 |
Clinical Implementation of Biologics and Small Molecules in the Treatment of Hidradenitis Suppurativa.
Topics: Adalimumab; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Biological Products; CD40 Anti | 2021 |
3 trials available for thalidomide and Acne Inversa
| Article | Year |
|---|---|
Apremilast for moderate hidradenitis suppurativa: no significant change in lesional skin inflammatory biomarkers.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antigens, CD; Antigens, Differentiation, T-Lymphocyt | 2019 |
Apremilast for moderate hidradenitis suppurativa: Results of a randomized controlled trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Female; Hidradenitis Suppurativ | 2019 |
Apremilast for the Treatment of Mild-to-Moderate Hidradenitis Suppurativa in a Prospective, Open-Label, Phase 2 Study
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Female; Gastrointestinal Diseases; Hidradenitis Supp | 2019 |
7 other studies available for thalidomide and Acne Inversa
| Article | Year |
|---|---|
Successful treatment of hidradenitis suppurativa and Crohn's disease with combined guselkumab and apremilast.
Topics: Antibodies, Monoclonal, Humanized; Crohn Disease; Hidradenitis Suppurativa; Humans; Thalidomide | 2022 |
One drug and two diseases: A case of multidrug-resistant hidradenitis suppurativa and psoriasis treated with apremilast.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Drug Resistance, Multiple; Hidradenitis Suppurativa; Humans | 2019 |
A case of hidradenitis suppurativa successfully treated with apremilast in a patient with psoriasis and SAMPUS.
Topics: Hidradenitis Suppurativa; Humans; Psoriasis; Thalidomide | 2020 |
Long-term treatment with apremilast in hidradenitis suppurativa: A 2-year follow-up of initial responders.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Duration of Therapy; Female; Follow-Up Studies; Hidr | 2021 |
Apremilast in the treatment of moderate to severe hidradenitis suppurativa: A case series of 9 patients.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Dose-Response Relationship, Dr | 2017 |
Thalidomide in Severe Hidradenitis Suppurativa: A Therapeutic Option.
Topics: Adolescent; Adult; Female; Hidradenitis Suppurativa; Humans; Immunosuppressive Agents; Male; Remissi | 2019 |
Successful treatment of superficial pyoderma gangrenosum associated with hidradenitis suppurativa with adalimumab.
Topics: Adalimumab; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Com | 2010 |